ESMO21: MONALEESA-2 trial demonstrates overall survival benefit - Oncology Central
Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry - The Lancet Regional Health – Europe
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer | NEJM
Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial | Breast Cancer Research | Full Text
Overall survival in the ITT population and by subgroup. a Kaplan-Meier... | Download Scientific Diagram
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer - ScienceDirect
Safety and impact of dose reductions on efficacy in the randomised MONALEESA -2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer | British Journal of Cancer
Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer | npj Breast Cancer
IJMS | Free Full-Text | Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis
Ribociclib Improves Progression-free Survival in Advanced Breast Cancer | ESMO
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer | NEJM
MONALEESA-2 subgroup analysis of locally assessed PFS. Data cut-off, 2... | Download Scientific Diagram
Kaplan–Meier analysis of locally assessed progression-free survival in... | Download Scientific Diagram
MONALEESA clinical program: a review of ribociclib use in different clinical settings | Future Oncology
GS2-01: "Overall survival subgroup analysis by metastatic site from the phase3 MONALEESA-2..." - YouTube
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer | NEJM
MONALEESA-2: Overall Survival Benefit Demonstrated in HR+ Advanced Breast Cancer with CDK 4/6 Inhibitor - The Medical Xchange
Final Overall Survival Analysis of MONALEESA-2 - The ASCO Post
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer | NEJM
Asco 2019 – Novartis looks to premenopausal survival to reinvigorate Kisqali | Evaluate
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer | NEJM
Efficacy of KISQALI® (ribociclib) + AI in Postmenopausal | HCP
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - Annals of Oncology
2021 Update on Systemic Therapy for Breast Cancer | Published in healthbook TIMES Oncology Hematology
